Pharmadrug Inc. (TSE:PHRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaDrug Inc. has announced the appointment of Dr. David Kideckel, an experienced pharma industry executive, as the new Chairman of the Board, signaling a strategic move as the company advances its drug development programs. The company is poised for a ‘transformational’ year with progress in its PD-001 drug for oncology and infectious diseases, and advancements in biosynthetic pharmaceutical manufacturing through SecureDose. PharmaDrug’s subsidiary Sairiyo is moving forward with a Phase 1 clinical study in Australia for PD-001, leveraging the country’s R&D tax incentives.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.